VNDA - יחס חוב להיוון בספרים Vanda Pharma

Vanda Pharmaceuticals (VNDA) maintains strong niche positions in the psychoneurology sector, protecting profits with patents against cheap generics. Revenues are based on sleep correction agents, although the risk of losing exclusive rights creates volatility, which currently stands at 0.11. The market price action of the securities is presented below; meanwhile, Vanda Pharmaceuticals (VNDA) is implementing eco-friendly synthesis methods and strictly adhering to medical trial ethics.

The erosion of patent protection for Vanda Pharmaceuticals (VNDA) products is forcing the company to optimize its capital structure to maintain competitiveness. This debt-to-book capitalization ratio measures the proportion of borrowed funds within the total capital, allowing investors to quickly assess the risk of insolvency or the pace of leverage-driven expansion, which is critical during a decline in the market value of assets.